• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Editor's Pick

Eyenovia to end eye drug study, cut 50% of its workforce

by November 16, 2024
written by November 16, 2024

(Reuters) -Eyenovia said on Friday it will discontinue a late-stage study for its experimental drug-device combination to treat near-sightedness and cut about 50% of its workforce.

Shares of the company were down nearly 70% at close of trading on Friday.

The drug, a low-dose atropine, was being tested with the company’s experimental drug-delivery device, Optejet, as a potential treatment for progressive myopia in children aged between 3 and 12.

An independent committee reviewed the safety and efficacy data from 252 trial participants and found that the rate of myopia progression was not significantly different between the treatment arm and placebo.

All doses of the drug appeared to be well-tolerated with “mild and infrequent” side-effects, the company said.

Optejet delivers the drug in microdoses and reduces chances of overdosing compared to conventional eyedroppers, according to the company.

The drug developer said it plans to review the data more thoroughly and evaluate strategic options, including a business combination, reverse merger and/or sale of assets.

The company said its remaining staff will be focused on the development of the second generation of Optejet.

Earlier this year, Eyenovia (NASDAQ:EYEN) had gained U.S. approval for its eye drops to reduce inflammation and pain in patients who have undergone eye surgery.

The company also markets a pupil-dilating spray, Mydcombi, for use with Optejet during eye examinations.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Mexico budget proposal trims 2025 deficit, sees better growth
next post
In El Salvador, crypto investors cheer Trump-powered Bitcoin rally

You may also like

China central bank conducts 1.7 trln yuan of...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

ECB president fears loss of central bank independence

January 27, 2025

European tech shares tumble as China’s AI push...

January 27, 2025

Futures slip as investors eye China’s latest AI...

January 27, 2025

Markets may be repeating the mistake of 2019,...

January 27, 2025

How billionaire Caltagirone could influence Italy’s banking M&A...

January 27, 2025

How Italy’s MPS went from near collapse to...

January 27, 2025

Analysis-To weather Trump, emerging market investors look to...

January 27, 2025

Chinese AI startup DeepSeek overtakes ChatGPT on Apple...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks

      June 26, 2025
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

      June 26, 2025
    • Bumble shares jump 26% as dating company plans to axe 30% of workforce

      June 26, 2025
    • Small-business AI use is lagging, but one firm is channeling Sherlock Holmes and knocking out ‘grunt work’

      June 25, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (534)
    • Stock (6,426)

    Latest News

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

    Popular News

    • HMC Capital to buy data centre group Global Switch Australia in $1.3 billion deal
    • Analysis-Bears circle China’s yuan gearing for Trump win

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy